KURAKura Oncology, Inc.
$9.61+3.5% 1Y
$9.61
$7.4052 weeks$13.59
Latest close: below its 200-day averageOct 23, 2026what changed →
Is the price fair?
What KURA's price assumes
Kura Oncology, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 12.6× revenue.
12.6
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 20.1
Price / book · as of 2026-Q2
- EV / sales
- 6.02
EV / sales
Details›
- Price / bookas of 2026-Q2
- 20.1
- EV / EBIToperating margin −412%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 6.02
- Market capitalisation89.0 million shares, counted Aug 7, 2026
- $854M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #101 of 194 by RyuScore